Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?
Identifieur interne : 000637 ( Hal/Checkpoint ); précédent : 000636; suivant : 000638Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?
Auteurs : Jean-Michel Senard [France] ; Atul Pathak [France]Source :
- Revue Neurologique [ 0035-3787 ] ; 2010-10.
Abstract
The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.
Url:
DOI: 10.1016/j.neurol.2010.07.007
Links toward previous steps (curation, corpus...)
Links to Exploration step
Hal:inserm-00550867Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING"> <orgName>Service de Pharmacologie Clinique</orgName>
<desc> <address> <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-300075" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID"> <orgName>CHU Toulouse [Toulouse]</orgName>
<desc> <address> <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING"> <orgName>Service de Pharmacologie Clinique</orgName>
<desc> <address> <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-300075" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID"> <orgName>CHU Toulouse [Toulouse]</orgName>
<desc> <address> <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:inserm-00550867</idno>
<idno type="halId">inserm-00550867</idno>
<idno type="halUri">http://www.hal.inserm.fr/inserm-00550867</idno>
<idno type="url">http://www.hal.inserm.fr/inserm-00550867</idno>
<idno type="doi">10.1016/j.neurol.2010.07.007</idno>
<date when="2010-10">2010-10</date>
<idno type="wicri:Area/Hal/Corpus">000784</idno>
<idno type="wicri:Area/Hal/Curation">000784</idno>
<idno type="wicri:Area/Hal/Checkpoint">000637</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000637</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING"> <orgName>Service de Pharmacologie Clinique</orgName>
<desc> <address> <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-300075" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID"> <orgName>CHU Toulouse [Toulouse]</orgName>
<desc> <address> <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING"> <orgName>Service de Pharmacologie Clinique</orgName>
<desc> <address> <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-300075" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID"> <orgName>CHU Toulouse [Toulouse]</orgName>
<desc> <address> <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1016/j.neurol.2010.07.007</idno>
<series><title level="j">Revue Neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date type="datePub">2010-10</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.</div>
</front>
</TEI>
<hal api="V3"> <titleStmt> <title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author role="crp"> <persName> <forename type="first">Jean-Michel</forename>
<surname>Senard</surname>
</persName>
<email type="md5">fc41bd7a33812b6f1c2e2f370db649c1</email>
<email type="domain">cict.fr</email>
<idno type="halauthorid">560724</idno>
<affiliation ref="#struct-136659"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Atul</forename>
<surname>Pathak</surname>
</persName>
<idno type="halauthorid">425054</idno>
<affiliation ref="#struct-136659"></affiliation>
<affiliation ref="#struct-27489"></affiliation>
</author>
<editor role="depositor"> <persName> <forename>Marie Francoise</forename>
<surname>Simon</surname>
</persName>
<email type="md5">8ea1139230ec722c2221baad7d89e5e5</email>
<email type="domain">inserm.fr</email>
</editor>
</titleStmt>
<editionStmt> <edition n="v1" type="current"> <date type="whenSubmitted">2010-12-31 15:12:48</date>
<date type="whenModified">2011-01-03 14:32:47</date>
<date type="whenReleased">2011-01-03 14:32:47</date>
<date type="whenProduced">2010-10</date>
</edition>
<respStmt> <resp>contributor</resp>
<name key="118088"> <persName> <forename>Marie Francoise</forename>
<surname>Simon</surname>
</persName>
<email type="md5">8ea1139230ec722c2221baad7d89e5e5</email>
<email type="domain">inserm.fr</email>
</name>
</respStmt>
</editionStmt>
<publicationStmt> <distributor>CCSD</distributor>
<idno type="halId">inserm-00550867</idno>
<idno type="halUri">http://www.hal.inserm.fr/inserm-00550867</idno>
<idno type="halBibtex">senard:inserm-00550867</idno>
<idno type="halRefHtml">Revue Neurologique, Elsevier Masson, 2010, 166 (10), pp.779-84. <10.1016/j.neurol.2010.07.007></idno>
<idno type="halRef">Revue Neurologique, Elsevier Masson, 2010, 166 (10), pp.779-84. <10.1016/j.neurol.2010.07.007></idno>
</publicationStmt>
<seriesStmt> <idno type="stamp" n="INSERM">INSERM - Institut national de la santé et de la recherche médicale</idno>
<idno type="stamp" n="UNIV-TLSE3">Université Paul Sabatier - Toulouse III</idno>
</seriesStmt>
<notesStmt> <note type="audience" n="2">International</note>
<note type="popular" n="0">No</note>
<note type="peer" n="1">Yes</note>
</notesStmt>
<sourceDesc> <biblStruct> <analytic> <title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author role="crp"> <persName> <forename type="first">Jean-Michel</forename>
<surname>Senard</surname>
</persName>
<email type="md5">fc41bd7a33812b6f1c2e2f370db649c1</email>
<email type="domain">cict.fr</email>
<idno type="halauthorid">560724</idno>
<affiliation ref="#struct-136659"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Atul</forename>
<surname>Pathak</surname>
</persName>
<idno type="halauthorid">425054</idno>
<affiliation ref="#struct-136659"></affiliation>
<affiliation ref="#struct-27489"></affiliation>
</author>
</analytic>
<monogr> <idno type="halJournalId" status="VALID">21340</idno>
<idno type="issn">0035-3787</idno>
<title level="j">Revue Neurologique</title>
<imprint> <publisher>Elsevier Masson</publisher>
<biblScope unit="volume">166</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="pp">779-84</biblScope>
<date type="datePub">2010-10</date>
</imprint>
</monogr>
<idno type="doi">10.1016/j.neurol.2010.07.007</idno>
<idno type="pubmed">20817229</idno>
</biblStruct>
</sourceDesc>
<profileDesc> <langUsage> <language ident="en">English</language>
</langUsage>
<textClass> <classCode scheme="mesh">Antiparkinson Agents</classCode>
<classCode scheme="mesh">Diagnosis, Differential</classCode>
<classCode scheme="mesh">Humans</classCode>
<classCode scheme="mesh">Multiple System Atrophy</classCode>
<classCode scheme="mesh">Parkinson Disease</classCode>
<classCode scheme="mesh">Shy-Drager Syndrome</classCode>
<classCode scheme="halTypology" n="ART">Journal articles</classCode>
</textClass>
<abstract xml:lang="en">The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.</abstract>
</profileDesc>
</hal>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Hal/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000637 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Hal/Checkpoint/biblio.hfd -nk 000637 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Hal |étape= Checkpoint |type= RBID |clé= Hal:inserm-00550867 |texte= Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment? }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |